Cargando…

ALK Inhibitors, a Pharmaceutical Perspective

In 2007, the ALK tyrosine kinase was described as a potential therapeutic target for a subset of non-small-cell lung cancer patients. Clinical proof of concept, culminating in the recent approval by the Food and Drug Administration of the Pfizer drug crizotinib followed in record time. The drug was...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardini, Elena, Galvani, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356102/
https://www.ncbi.nlm.nih.gov/pubmed/22655263
http://dx.doi.org/10.3389/fonc.2012.00017

Ejemplares similares